Casebia Counts On Collaboration In Its Climb To Leadership In Gene Therapy
An Interview With CEO Jim Burns
Casebia Therapeutics, a three-year old start-up in the hotly contested gene therapy space, is the product of a remarkably relaxed joint venture between the German multinational giant Bayer and CRISPR Therapeutics, a leader in conducting the first clinical trial involving the CRISPR-Cas9 editing platform.
You may also be interested in...
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.
Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health: can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.